Prenatal Screening for 22q11.2 Deletion Using a Targeted Microarray-Based Cell-Free DNA Test
Open Access
- 8 November 2017
- journal article
- research article
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 44 (4) , 299-304
Abstract
Objective: To determine the performance of a targeted microarray-based cell-free DNA (cfDNA) test (Harmony Prenatal Test®) for the identification of pregnancies at increased risk for 22q11.2 deletion. Methods: Test performance was determined in 2 steps including a total of 1,953 plasma samples. Analytical validation was performed in 1,736 plasma samples. Clinical verification of performance was performed in an additional 217 prospectively ascertained samples from pregnancies with fetal deletion status determined by diagnostic testing. Results: Analytical sensitivity was 75.4% (95% CI: 67.1–82.2%) based on 122 samples with deletions ranging from 1.96 to 3.25 Mb. In 1,614 presumed unaffected samples, specificity was determined to be at least 99.5% (95% CI: 99.0–99.7%). In the clinical cohort, 5 of 7 samples from pregnancies affected with 22q11.2 deletion were determined to have a high probability of deletion. There were no false positive results in the 210 unaffected samples in this cohort. These clinical data are consistent with the performance demonstrated in the analytical validation. Conclusions: cfDNA testing using a targeted microarray-based technology is able to identify pregnancies at increased risk for 22q11.2 deletions of 3.0 Mb and smaller while maintaining a low false positive rate.Keywords
This publication has 25 references indexed in Scilit:
- Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromesAmerican Journal of Obstetrics and Gynecology, 2015
- Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysisUltrasound in Obstetrics & Gynecology, 2015
- Microarray-Based Cell-Free DNA Analysis Improves Noninvasive Prenatal TestingFetal Diagnosis and Therapy, 2014
- Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasmaPrenatal Diagnosis, 2014
- Chromosomal Microarray versus Karyotyping for Prenatal DiagnosisNew England Journal of Medicine, 2012
- Digital PCR Analysis of Maternal Plasma for Noninvasive Detection of Sickle Cell AnemiaClinical Chemistry, 2012
- Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- Selective analysis of cell‐free DNA in maternal blood for evaluation of fetal trisomyPrenatal Diagnosis, 2012
- Practical Guidelines for Managing Patients with 22q11.2 Deletion SyndromeThe Journal of Pediatrics, 2011
- Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardationAmerican Journal of Medical Genetics Part A, 2006